Generate Biomedicines (NASDAQ:GENB) Trading Up 6.6% – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price traded up 6.6% on Monday . The stock traded as high as $17.66 and last traded at $17.5550. Approximately 184,085 shares traded hands during trading, a decline of 73% from the average daily volume of 670,269 shares. The stock had previously closed at $16.47.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating on the stock. The Goldman Sachs Group started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective for the company. Morgan Stanley increased their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Finally, Piper Sandler initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Performance

The business has a 50 day simple moving average of $13.76.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.